Exchange: NASDAQ Global Select Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Current Signal: BUY (auto-tracking)
3.15% $6.87
/ 7 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 209.86 mill |
EPS: | -2.14 |
P/E: | -3.21 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 30.55 mill |
Avg Daily Volume: | 0.202 mill |
RATING 2024-05-07 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -3.21 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -3.21 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
$-5.11 (-174.40%) $-11.98 |
Date: 2024-05-07 |
Expected Trading Range (DAY) |
---|
$ 6.47 - 7.31 ( +/- 6.10%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Schechter Joshua | Buy | 9 554 | Common Stock |
2024-02-01 | Schechter Joshua | Sell | 9 554 | Restricted Stock Units |
2024-02-01 | Calloway Nathaniel | Buy | 3 981 | Common Stock |
2024-02-01 | Calloway Nathaniel | Sell | 3 981 | Restricted Stock Unit |
2024-02-01 | Obus Nelson | Buy | 9 554 | Common Stock |
INSIDER POWER |
---|
67.76 |
Last 64 transactions |
Buy: 1 321 123 | Sell: 150 606 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $6.87 (3.15% ) |
Volume | 0.207 mill |
Avg. Vol. | 0.202 mill |
% of Avg. Vol | 102.57 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $8.34 | N/A | Active |
---|
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.